----

|                          |
|--------------------------|
|                          |  |
| 001-10315                | 63-0860407 |
| (Commission File Number) | (I.R.S. Employer Identification No.) |
|                     |   |

|        |
|--------|
|        |  |
| £ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|   |   |
| £ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|   |   |
| £ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|   |   |
| £ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

----

----

|         |                                              |
|---------|----------------------------------------------|
| • | Adjusted EBITDA of $520 to $530 million; and |

|         |                                                                                              |
|---------|----------------------------------------------------------------------------------------------|
| • | Earnings per share from continuing operations attributable to HealthSouth of $2.87 to $2.93. |

|         |                                                               |
|---------|---------------------------------------------------------------|
| • | Revenue growth before sequestration of between 5.0% and 6.0%; |

|         |                                            |
|---------|--------------------------------------------|
| ▪ | Discharge growth of between 3.0% and 4.0%; |

|         |                                                                             |
|---------|-----------------------------------------------------------------------------|
| ▪ | Revenue per discharge growth before sequestration of between 2.3% and 2.6%; |

|         |                                                                                                             |
|---------|-------------------------------------------------------------------------------------------------------------|
| • | Adjusted EBITDA reduction of approximately $16 million, net of noncontrolling interests, for sequestration; |

|         |                                                         |
|---------|---------------------------------------------------------|
| • | A planned merit increase in the fourth quarter of 2013; |

|         |                                                                                                                                |
|---------|--------------------------------------------------------------------------------------------------------------------------------|
| • | Increased operating expenses of approximately $2 million due to continued installation of new clinical information system; and |

|         |                                                                                             |
|---------|---------------------------------------------------------------------------------------------|
| • | Higher noncontrolling interests expense of $3 million due to changes at two joint ventures. |

----

----

|                                                    |
|----------------------------------------------------|
|                                                    |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                               | Three Months Ended |   | Six Months Ended |   |   |   |   |   |   |   |   |   |   |
|                                               | June 30, |   | June 30, |   | Year Ended December 31, |
|                                               | 2013 |   | 2012 |   | 2013 |   | 2012 |   | 2012 |   | 2011 |   | 2010 |   | 2009 |   | 2008 |
|                                               | (In Millions) |
| Net cash provided by operating activities          | $ | 105.4 |  |   | $ | 114.0 |  |   | $ | 226.8 |  |   | $ | 195.0 |  |   | $ | 411.5 |  |   | $ | 342.7 |  |   | $ | 331.0 |  |   | $ | 406.1 |  |   | $ | 227.2 |  |
| Provision for doubtful accounts                    | (7.0 | ) |   | (6.5 | ) |   | (14.4 | ) |   | (12.8 | ) |   | (27.0 | ) |   | (21.0 | ) |   | (16.4 | ) |   | (30.7 | ) |   | (23.0 | ) |
| Professional fees—accounting, tax, and legal | 2.2 |  |   | 5.5 |  |   | 3.6 |  |   | 9.1 |  |   | 16.1 |  |   | 21.0 |  |   | 17.2 |  |   | 8.8 |  |   | 44.4 |  |
| Interest expense and amortization of debt          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| discounts and fees                                 | 24.4 |  |   | 23.0 |  |   | 48.6 |  |   | 46.3 |  |   | 94.1 |  |   | 119.4 |  |   | 125.6 |  |   | 125.7 |  |   | 159.3 |  |
| UBS Settlement proceeds, gross                     | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (100.0 | ) |   | — |  |
| Equity in net income of nonconsolidated            |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| affiliates                                         | 3.3 |  |   | 3.1 |  |   | 6.2 |  |   | 6.4 |  |   | 12.7 |  |   | 12.0 |  |   | 10.1 |  |   | 4.6 |  |   | 10.6 |  |
| Net income attributable to noncontrolling          |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  interests in continuing operations           | (13.8 | ) |   | (13.2 | ) |   | (28.4 | ) |   | (25.8 | ) |   | (50.9 | ) |   | (47.0 | ) |   | (40.9 | ) |   | (33.3 | ) |   | (29.8 | ) |
| Amortization of debt discounts and fees            | (1.0 | ) |   | (0.9 | ) |   | (2.0 | ) |   | (1.8 | ) |   | (3.7 | ) |   | (4.2 | ) |   | (6.3 | ) |   | (6.6 | ) |   | (6.5 | ) |
| Distributions from nonconsolidated affiliates      | (1.6 | ) |   | (2.2 | ) |   | (5.0 | ) |   | (5.5 | ) |   | (11.0 | ) |   | (13.0 | ) |   | (8.1 | ) |   | (8.6 | ) |   | (10.9 | ) |
| Current portion of income tax (benefit) expense    | (1.3 | ) |   | 2.2 |  |   | 0.5 |  |   | 4.3 |  |   | 5.9 |  |   | 0.6 |  |   | 2.9 |  |   | (7.0 | ) |   | (72.8 | ) |
| Change in assets and liabilities                   | 23.2 |  |   | 1.5 |  |   | 36.2 |  |   | 38.4 |  |   | 58.1 |  |   | 41.4 |  |   | 5.7 |  |   | 9.1 |  |   | 58.0 |  |
| Net premium paid on bond                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| issuance/redemption                                | — |  |   | — |  |   | — |  |   | — |  |   | 1.9 |  |   | 22.8 |  |   | — |  |   | — |  |   | — |  |
| Net cash (provided by) used in operating           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| activities of discontinued operations              | (0.5 | ) |   | (1.3 | ) |   | 0.2 |  |   | (1.7 | ) |   | (2.0 | ) |   | (9.1 | ) |   | (13.2 | ) |   | (5.7 | ) |   | (32.5 | ) |
| Other, including realized losses and (gains)       |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|  on sales of investments                      | 1.2 |  |   | (0.1 | ) |   | 1.5 |  |   | 0.2 |  |   | 0.2 |  |   | 0.6 |  |   | 2.0 |  |   | 1.3 |  |   | (1.4 | ) |
| Adjusted EBITDA                                    | $ | 134.5 |  |   | $ | 125.1 |  |   | $ | 273.8 |  |   | $ | 252.1 |  |   | $ | 505.9 |  |   | $ | 466.2 |  |   | $ | 409.6 |  |   | $ | 363.7 |  |   | $ | 322.6 |  |

----

----

----

|        |
|--------|
|        |  |  |
|   |   |   |
| By:    | /S/   JOHN P. WHITTINGTON |
|   | Name: | John P. Whittington |
|   | Title: | Executive Vice President, General Counseland Corporate Secretary |